Debiopharm, Pharmaleads Sign License Agreement for Pain Treatment

February 9, 2009
Debiopharm Group, a global biopharmaceutical development specialist … and Pharmaleads SAS, a science driven drug discovery and early development company, announced the signature of an exclusive license agreement for the development, registration and commercialisation of a small molecule called Debio 0827 or PL37, about to enter phase I clinical trials.
Yahoo! Finance